Target-Oriented Drug Delivery 2
Target-Oriented Drug Delivery 2
Three approaches for drug targeting Biological active agents that are both potent and specific ·The prodrug approach Targeted drug delivery systems
Three approaches for drug targeting • Biological active agents that are both potent and specific • The prodrug approach • Targeted drug delivery systems
The Gleevec miracle Blocks the activity of the BCR-ABL enzyme that ADP ATP causes the cells to become PO, cancerous and multiply TYR bcr-abl bcr-abl tyrosine Sub- tyrosine Sub- Has ability to distinguish kinase strate kinase strate between carcinomic WBC and normal WBC Altered cellular adhesion Ahered cellular adhesion Abnormal prolileraton Abnormal peolferaton Inhibon of apootosis nbition of apoptosis Effective in gastrointestinal CML stromal tumor(GIST),and acute lymphocytic leukemia The Oncologist 2001,;6:233-238 June 2001
The Gleevec miracle • Blocks the activity of the BCR-ABL enzyme that causes the cells to become cancerous and multiply • Has ability to distinguish between carcinomic WBC and normal WBC • Effective in gastrointestinal stromal tumor (GIST), and acute lymphocytic leukemia The Oncologist 2001;6:233-238 June 2001
Philadelphia Chromosome? ·A shortened Normal Translocation Chromosome Chromosome chromosome 22 90+ Normal resulting from the Chromosome Philadelphia 22 Chromosome translocation between chromosome 9 and chromosome 22 c-ab ·Produces BCR-ABL oncogene http://www.hhmi.org/bulletin/dec2001/gleevec/
Philadelphia Chromosome? • A shortened chromosome 22 resulting from the translocation between chromosome 9 and chromosome 22 • Produces BCR-ABL oncogene http://www.hhmi.org/bulletin/dec2001/gleevec/
Of the 54 patients in the more advanced stage, 98%of the patients reached a hematologic response Recent studies reported in New England Journal of Medicine (NEJM)in 2003: - Of 1,106 patients,74%of newly diagnosed patients in the chronic phase treated with Gleevec achieved a complete cytogenic response,compared to 8%of those treated with interferon and cytosine arabinoside. - 92%of the patients taking Gleevec had an improved overall progression-free survival
• Of the 54 patients in the more advanced stage, 98% of the patients reached a hematologic response • Recent studies reported in New England Journal of Medicine (NEJM) in 2003: – Of 1,106 patients, 74% of newly diagnosed patients in the chronic phase treated with Gleevec achieved a complete cytogenic response, compared to 8% of those treated with interferon and cytosine arabinoside. – 92% of the patients taking Gleevec had an improved overall progression-free survival